Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDARD: Lanreotide Autogel in Refractory Diarrhea
NCT00891371Phase 3Completed
- Sponsor
- Ipsen
- Start
- Jul 2009
- Primary completion
- Aug 2012
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lanreotide in diarrhea, sponsored by Ipsen. Primary endpoint: Percentage of Patients Having Minimum Reduction of 50% or Normalization (≤3 Stools/24hours) in the Mean Number of Stools at 28 days. Started Jul 2009; status: completed.
02
Drugs
lanreotide
03
Conditions
diarrhea
Beyond the preview
Go deeper on NCT00891371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00891371.